Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 5/20 | 1.00 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 1.00 |
| ▸ | EGLN3 | Q9H6Z9 | 5/20 | 1.00 |
| ▸ | P4HTM | Q9NXG6 | 5/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | NT5E | P21589 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ALB | P02768 | 2/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | GLI1 | P08151 | 2/20 | 0.54 |
| ▸ | RORC | P51449 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.54 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20072718 | 1.00 | EGLN2 (1.00) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL13293163 | 0.91 | EGLN2 (0.83) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL14086933 | 0.91 | EGLN2 (0.83) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL2620462 | 0.84 | EGLN2 (0.72) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL21435975 | 0.83 | GPBAR1 (0.71) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL21435881 | 0.82 | EGLN2 (0.69) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL20072644 | 0.81 | EGLN2 (0.68) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL13098071 | 0.81 | EGLN2 (0.68) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| Betulin-3,28-Dioxime SCHEMBL13098079 | 0.81 | SLC10A1 (0.69) | EGLN2EGLN1EGLN3P4HTMGPBAR1 | |
| SCHEMBL13293178 | 0.81 | GPBAR1 (0.69) | EGLN2EGLN1EGLN3P4HTMGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766855-B2 | Hydroxamate triterpenoid derivatives | VIVACELL BIOTECHNOLOGY ESPAÑA, S.L. (ES) | 2020-09-08 | — | — | US | disclosed |
| WO-2018069086-A1 | HYDROXAMATE TRITERPENOID DERIVATIVES | VIVACELL BIOTECHNOLOGY ESPAÑA S.L. (ES) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766855-B2 | Hydroxamate triterpenoid derivatives | STAT3, EPOR, TXNRD2 | EGLN2 10/4885EGLN1 34/4885EGLN3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.